Aventis Nasacort HFA approved
Executive Summary
FDA clears Aventis'Nasacort HFA (triamcinolone acetonide) April 7 for nasal symptoms of seasonal and perennial allergic rhinitis for patients six years old and older. The drug is the first FDA-approved HFA nasal steroid; Aventis markets Nasacort AQ, the aqueous solution of triamcinolone, in a non-CFC metered-dose pump spray...
You may also be interested in...
GSK Flovent HFA approved
GlaxoSmithKline's CFC-free version of Flovent (fluticasone) for the treatment of asthma as prophylactic therapy in adults and adolescents 12 years and older clears FDA May 14. The drug is the second HFA nasal steroid to be approved after Aventis' Nasacort HFA inhaler for allergic rhinitis was cleared in April (1"The Pink Sheet" April 12, 2004, In Brief). A proposed rule on CFC-containing products is near publication (2"The Pink Sheet" April 26, 2004, In Brief)...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.